Friday, January 19, 2024 10:29:37 AM
Here is the problem here.
With all the past missed promises SHMN earned the honor of being a Missouri Stock (show me),
The problem lies, if they have turned the corner and things actually start getting done as it now appears they are, those that wait for Missouri , well you will be paying 10 to 100 times more for the stock.
It is obvious Agulair is now the face of the company going forward (significant change in company events)
It is obvious the company has changed how it makes public claims . One has to look no further than the difference how Gabapentin and Levetiracetam announcements were made public. Gabapentin an out and and out lie while Levetiracetam FDA verifiable.
Could it end up being the same old same old? Absolutely!. Or can the new sheriff in town actually end the chaos and bring order and prosperity? Possible!
At 0.0017 is it worth the risk to find out?
Speaking only for myself, I believe so..
With all the past missed promises SHMN earned the honor of being a Missouri Stock (show me),
The problem lies, if they have turned the corner and things actually start getting done as it now appears they are, those that wait for Missouri , well you will be paying 10 to 100 times more for the stock.
It is obvious Agulair is now the face of the company going forward (significant change in company events)
It is obvious the company has changed how it makes public claims . One has to look no further than the difference how Gabapentin and Levetiracetam announcements were made public. Gabapentin an out and and out lie while Levetiracetam FDA verifiable.
Could it end up being the same old same old? Absolutely!. Or can the new sheriff in town actually end the chaos and bring order and prosperity? Possible!
At 0.0017 is it worth the risk to find out?
Speaking only for myself, I believe so..
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
